For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Oncomed Pharmaceuticals, Inc.

USPTO Granted Patents = 94

CIPO Patents = 1

EPO Patents = 24

Forward Citations = 874

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Austin L Gurney (80 out of 719 patents)

Timothy Charles Hoey (37 out of 37 patents)

Aaron Sato (29 out of 77 patents)

4. Sanjeev Satyal (26 out of 33 patents)

5. Fumiko Takada Axelrod (19 out of 24 patents)

6. John A Lewicki (18 out of 52 patents)

7. Christopher John Bond (13 out of 18 patents)

8. Maureen Fitch Bruhns (11 out of 11 patents)

9. Edward Thein Htun Van Der Horst (10 out of 15 patents)

10. Robert Joseph Stagg (8 out of 9 patents)

11. Satyajit Sujit Kumar Mitra (7 out of 7 patents)

12. Jakob Dupont (5 out of 9 patents)

13. Steven Eugene Benner (5 out of 5 patents)

14. Alexandra L L Lazetic (5 out of 7 patents)

15. Wan-ching Yen (5 out of 5 patents)

Core Competencies:

Combination Therapy

DLL4 Antagonist

VEGF Binding Agents

Immunotherapy

Frizzled-Binding Agents

Notch Receptor Binding

Wnt Pathway Inhibitor

Monoclonal Antibodies

Tumor Necrosis Factor

Cancer Treatment

Polynucleotides

Anti-Hypertensive Agents

94 patents: Sort by Forward Citations

1. 11046760 - Combination therapy for treatment of disease (2021-06-29),

2. 10870693 - Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent (2020-12-22),

3. 10730940 - VEGF/DLL4 binding agents and uses thereof (2020-08-04),

4. 10544219 - TIGIT-binding agents and uses thereof (2020-01-28),

5. 10232017 - Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides (2019-03-19),

6. 10112997 - Tight-binding agents and uses thereof (2018-10-30),

7. 10064937 - Treatment of dermal fibrosis (2018-09-04),

8. 9987357 - Methods and monitoring of treatment with a WNT pathway inhibitor (2018-06-05),

9. 9982042 - Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent (2018-05-29),

10. 9914771 - Method for making heteromultimeric molecules (2018-03-13),

11. 9879084 - Modified immunoglobulin molecules that specifically bind human VEGF and DLL4 (2018-01-30),

12. 9873726 - Methods for identifying and isolating cells expressing a polypeptide (2018-01-23),

13. 9850311 - Compositions and methods for diagnosing and treating cancer (2017-12-26),

14. 9833500 - Immunotherapy with binding agents (2017-12-05),

15. 9732139 - Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor (2017-08-15),

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibody-based therapeutics to treat cancer. With a focus on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells, OncoMed aims to improve patient outcomes and transform the treatment of cancer. Through strategic collaborations and internal research efforts, the company is advancing multiple investigational candidates, which are evaluated through rigorous clinical trials to deliver innovative cancer therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

94 Patents

#18 in Redwood City, CA

#915 in California

#3,841 in US

#7,948 in the World

Redwood City, CA, United States of America

Oncomed Pharmaceuticals, Inc.

Forward Citations = 874

34 inventors:

Austin L Gurney (80 out of 719 patents)

Timothy Charles Hoey (37 out of 37 patents)

Aaron Sato (29 out of 77 patents)

4. Sanjeev Satyal (26 out of 33 patents)

5. Fumiko Takada Axelrod (19 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…